165 related articles for article (PubMed ID: 34303003)
21. The incidence of hepatocellular carcinoma is reduced in patients with chronic hepatitis B on long-term nucleos(t)ide analogue therapy.
Coffin CS; Rezaeeaval M; Pang JX; Alcantara L; Klein P; Burak KW; Myers RP
Aliment Pharmacol Ther; 2014 Dec; 40(11-12):1262-9. PubMed ID: 25312649
[TBL] [Abstract][Full Text] [Related]
22. Effects of pegylated interferon-α based therapies on functional cure and the risk of hepatocellular carcinoma development in patients with chronic hepatitis B.
Ren H; Huang Y
J Viral Hepat; 2019 Jul; 26 Suppl 1():5-31. PubMed ID: 31380584
[TBL] [Abstract][Full Text] [Related]
23. Histological responses of peginterferon alpha add-on therapy in patients with chronic hepatitis B with advanced liver fibrosis after long-term nucleos(t)ide analog treatment.
Li G; Zhang Q; Yu Y; Qiu C; Zhang H; Zhang M; Song Z; Yang Y; Hong J; Lu J; Li N; Tang Q; Xu L; Wang X; Zhang W; Chen Z
J Viral Hepat; 2019 Jul; 26 Suppl 1():50-58. PubMed ID: 31380590
[TBL] [Abstract][Full Text] [Related]
24. Real-world study on clinical outcomes of nucleos(t)ide analogues antiviral therapy in patients with chronic hepatitis B.
Sun Y; Zhang Y; Xu Y; Shu M; Bonroy K; Qiu H; Cai W
Epidemiol Infect; 2019 Jan; 147():e193. PubMed ID: 31364558
[TBL] [Abstract][Full Text] [Related]
25. Determinants of hepatocellular carcinoma in cirrhotic patients treated with nucleos(t)ide analogues for chronic hepatitis B.
Hsu YC; Wu CY; Lane HY; Chang CY; Tai CM; Tseng CH; Lo GH; Perng DS; Lin JT; Mo LR
J Antimicrob Chemother; 2014 Jul; 69(7):1920-7. PubMed ID: 24576950
[TBL] [Abstract][Full Text] [Related]
26. [Oral nucleos(t)ide analogues antiviral therapy reduces HBV-related HCC: consensus and contention].
Han C; Dou XG
Zhonghua Gan Zang Bing Za Zhi; 2021 Apr; 29(4):293-296. PubMed ID: 33979951
[TBL] [Abstract][Full Text] [Related]
27. Exploration of nucleos(t)ide analogs cessation in chronic hepatitis B patients with hepatitis B e antigen loss.
Xue Y; Zhang M; Li T; Liu F; Zhang LX; Fan XP; Yang BH; Wang L
World J Gastroenterol; 2021 Apr; 27(14):1497-1506. PubMed ID: 33911470
[TBL] [Abstract][Full Text] [Related]
28. [Liver histological status and clinic outcome in HBeAg-negative chronic hepatitis B with low viral load].
Deng DL; Jiang JN; Su MH; Wang RM; Zang WW; Ling XZ; Wei HL; Liang XS; Zhou HK; He WM; Guo RS
Zhonghua Gan Zang Bing Za Zhi; 2020 Dec; 28(12):1013-1017. PubMed ID: 34865348
[No Abstract] [Full Text] [Related]
29. High percentage atypical hepatocellular carcinoma in chronic hepatitis B patients treated with nucleos(t)ide analogs.
Lin CC; Bair MJ; Liu CY; Lin ZY; Chen CJ; Chen MJ; Chu CH; Wang HY; Shih SC; Wang TE
Medicine (Baltimore); 2019 Jan; 98(1):e13818. PubMed ID: 30608393
[TBL] [Abstract][Full Text] [Related]
30. Entecavir and Low Genetic Barrier Antiviral Agents for Hepatocellular Carcinoma in Hepatitis B Viral Cirrhosis: Propensity Score Matching.
Li T; Qu Y; Wang Y; Lin C; Yang B; Wang L
J Coll Physicians Surg Pak; 2019 Apr; 29(4):317-323. PubMed ID: 30925952
[TBL] [Abstract][Full Text] [Related]
31. The assessment of hepatocellular carcinoma risk in patients with chronic hepatitis B under antiviral therapy.
Varbobitis I; Papatheodoridis GV
Clin Mol Hepatol; 2016 Sep; 22(3):319-326. PubMed ID: 27729632
[TBL] [Abstract][Full Text] [Related]
32. Long-term outcomes of hepatitis B virus-related cirrhosis treated with nucleos(t)ide analogs.
Tsai MC; Chen CH; Hu TH; Lu SN; Lee CM; Wang JH; Hung CH
J Formos Med Assoc; 2017 Jul; 116(7):512-521. PubMed ID: 27720344
[TBL] [Abstract][Full Text] [Related]
33. The development of hepatocarcinoma after long-term antivirus treatment of Chinese patients with chronic hepatitis B virus infection: Incidence, long-term outcomes and predictive factors.
Li ZQ; Hu CL; Yu P; Gu XY; Zhang JJ; Li H; Zhang HY; Lv J; Liu YM; Zeng QL; Yan JY; Yu ZJ; Zhang Y
Clin Res Hepatol Gastroenterol; 2017 Jun; 41(3):311-318. PubMed ID: 28237828
[TBL] [Abstract][Full Text] [Related]
34. Four-year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients.
Su TH; Hu TH; Chen CY; Huang YH; Chuang WL; Lin CC; Wang CC; Su WW; Chen MY; Peng CY; Chien RN; Huang YW; Wang HY; Lin CL; Yang SS; Chen TM; Mo LR; Hsu SJ; Tseng KC; Hsieh TY; Suk FM; Hu CT; Bair MJ; Liang CC; Lei YC; Tseng TC; Chen CL; Kao JH;
Liver Int; 2016 Dec; 36(12):1755-1764. PubMed ID: 27634134
[TBL] [Abstract][Full Text] [Related]
35. Hepatitis B core-related antigen predicts disease progression and hepatocellular carcinoma in hepatitis B e antigen-negative chronic hepatitis B patients.
Kaneko S; Kurosaki M; Inada K; Kirino S; Hayakawa Y; Yamashita K; Osawa L; Sekiguchi S; Higuchi M; Takaura K; Maeyashiki C; Tamaki N; Yasui Y; Itakura J; Takahashi Y; Tsuchiya K; Nakanishi H; Izumi N
J Gastroenterol Hepatol; 2021 Oct; 36(10):2943-2951. PubMed ID: 34057248
[TBL] [Abstract][Full Text] [Related]
36. Fibrosis-matched outcomes between chronic hepatitis B patients with drug-induced virological response and inactive carriers.
Kim HS; Baatarkhuu O; Lee HW; Park JY; Kim DY; Ahn SH; Song K; Han KH; Kim BK; Kim SU
Liver Int; 2019 Jan; 39(1):81-89. PubMed ID: 30280461
[TBL] [Abstract][Full Text] [Related]
37. Nucleos(t)ide analogues associated with a reduced risk of hepatocellular carcinoma in hepatitis B patients: a population-based cohort study.
Wang JP; Kao FY; Wu CY; Hung YP; Chao Y; Chou YJ; Li CP
Cancer; 2015 May; 121(9):1446-55. PubMed ID: 25537961
[TBL] [Abstract][Full Text] [Related]
38. HBeAg-negative chronic hepatitis B: why do I treat my patients with nucleos(t)ide analogues?
Viganò M; Mangia G; Lampertico P
Liver Int; 2014 Feb; 34 Suppl 1():120-6. PubMed ID: 24373088
[TBL] [Abstract][Full Text] [Related]
39. Albumin-bilirubin score is associated with response to pegylated interferon and nucleos(t)ide analogues in chronic hepatitis B patients.
Xun Z; Liu C; Yu QQ; Lin JP; Huang JL; Yang TW; Wu WN; Wu SH; Ou QS
Clin Chim Acta; 2020 Mar; 502():120-127. PubMed ID: 31891671
[TBL] [Abstract][Full Text] [Related]
40. Association Between Fatty Liver and Cirrhosis, Hepatocellular Carcinoma, and Hepatitis B Surface Antigen Seroclearance in Chronic Hepatitis B.
Li J; Yang HI; Yeh ML; Le MH; Le AK; Yeo YH; Dai CY; Barnett S; Zhang JQ; Huang JF; Trinh HN; Wong C; Wong C; Hoang JK; Cheung R; Yu ML; Nguyen MH
J Infect Dis; 2021 Jul; 224(2):294-302. PubMed ID: 33249474
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
